Loading…

Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients

Abstract This report aims to more accurately define the frequency of the involvement of SRC Family Kinases (SFKs) in imatinib- and dasatinib-resistant CML patients. Clinical samples were analysed during in vivo treatment. We confirmed the high frequency of SFKs involvement in Tyrosine kinase inhibit...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2011-01, Vol.35 (1), p.38-43
Main Authors: Hayette, Sandrine, Chabane, Kaddour, Michallet, Mauricette, Michallat, Estelle, Cony-Makhoul, Pascale, Salesse, Stéphanie, Maguer-Satta, Véronique, Magaud, Jean-Pierre, Nicolini, Franck E
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract This report aims to more accurately define the frequency of the involvement of SRC Family Kinases (SFKs) in imatinib- and dasatinib-resistant CML patients. Clinical samples were analysed during in vivo treatment. We confirmed the high frequency of SFKs involvement in Tyrosine kinase inhibitor-resistant CML (52% of the cases) and even further in progressive disease and blast crises (60% of the cases). The SFKs deregulation is also observed in patients harboring BCR-ABL mutations. In T315I and F317L mutated patients, CML-resistance appears to be promoted by SFKs kinase protein reactivation once the BCR-ABL mutated clone has decreased on Omacetaxine.
ISSN:0145-2126
1873-5835
0145-2126
DOI:10.1016/j.leukres.2010.06.030